|Bid||0.00 x 3000|
|Ask||0.00 x 1100|
|Day's Range||14.38 - 14.85|
|52 Week Range||8.32 - 20.66|
|Beta (3Y Monthly)||2.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip sid...
Coherus BioSciences Inc NASDAQ NMS:CHRSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | PositiveShort interest is moderate for CHRS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CHRS are favorable, with net inflows of $1.69 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Coherus BioSciences, Inc.'s (NASDAQ:CHRS): Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The US$590m market-cap posted a loss in its most recent financial year of Read More...
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
Coherus BioSciences, Inc. (CHRS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Denny Lanfear became the CEO of Coherus BioSciences Inc (NASDAQ:CHRS) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call.
On a per-share basis, the Redwood City, California-based company said it had a loss of 87 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...